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Abstract—Fo ¨ rster resonance energy transfer (FRET) tech-
nology has been widely used in biological and biomedical
research and is a very powerful tool in elucidating protein
interactions in many cellular processes. Ubiquitination and
SUMOylation are multi-step cascade reactions, involving
multiple enzymes and protein–protein interactions. Here we
report the development of dissociation constant (Kd)
determination for protein–protein interaction and cell-based
high-throughput screening (HTS) assay in SUMOylation
cascade using FRET technology. These developments are
based on steady state and high efﬁciency of ﬂuorescent
energy transfer between CyPet and YPet fused with
SUMO1 and Ubc9, respectively. The developments in
theoretical and experimental procedures for protein inter-
action Kd determination and cell-based HTS provide novel
tools in afﬁnity measurement and protein interaction
inhibitor screening. The Kd determined by FRET between
SUMO1 and Ubc9 is compatible with those determined
with other traditional approaches, such as isothermal
titration calorimetry (ITC) and surface plasmon resonance
(SPR). The FRET-based HTS is pioneer in cell-based HTS.
Both Kd determination and cell-based HTS, carried out in
384-well plate format, provide powerful tools for large-scale
and high-throughput applications.
Keywords—SUMOylation, Fo ¨ rster resonance energy trans-
fer, Kd afﬁnity determination, High-throughput screening.
INTRODUCTION
Post-translational modiﬁcation by ubiquitin (Ub)
and ubiquitin-like (Ubls) proteins, such as SUMO,
plays critical roles in many physiological and patho-
logical processes in eukaryotes, such as signal trans-
ductions, genome integrity, protein transport, cell
cycles, and tumorigenesis.
1,6,10,18,28 SUMO, known as
Small Ubiquitin-related MOdiﬁer, has emerged as an
important protein modiﬁer in last decade. Composed
of ~100 amino acids, SUMO undergoes reversible
conjugation to the lysine residues of target proteins
(SUMOylation) via the catalysis of various enzymes
(Fig. 1). SUMOylation in a target-speciﬁc manner can
affect a target protein’s intracellular localization, its
ability to interact with other proteins or its transcrip-
tional activity.
10 SUMO is present in most eukaryotic
organisms, suggesting its critical roles in various
physiological processes. Although not completely
understood yet, SUMOylation of many proteins have
been linked to some human diseases including neuro-
degenerative diseases, viral infection, tumorigenesis,
and cancer metastasis.
1,3,16,25 (Fig. 1).
Analogous to ubiquitination, conjugation and
deconjugation of SUMO require the catalysis of multi-
pleenzymes(Fig. 1).SUMOissynthesizedasaprecursor
protein. Pre-SUMO is then recognized by SUMO-spe-
ciﬁcpeptidases(SENPs)andcleavedintoamatureform
with a C-terminal Gly–Gly motif.
27 The heterodimer
Aos1/Uba2, which is the SUMO E1 activating enzyme,
then forms a thioester bond with SUMO using the
energy from the degradation of ATP.
7,12,20 SUMO is
further transferred from the E1 enzyme to the active site
cysteine ofthe SUMO E2conjugating enzyme Ubc9.
9,11
With the help of SUMO E3 ligases in vivo, SUMO is
ﬁnally transferred from Ubc9 to the lysine residue of
target proteins.
10 SUMOylated proteins can then be
recognized by SENPs and SUMO is cleaved off for next
cycle of conjugation.
27 Protein–protein interactions are
crucial for SUMOylation to proceed.
Fo ¨ rster resonance energy transfer (FRET) is very
appealing for bioanalysis because of its intrinsic sen-
sitivity to nanoscale changes in D/A separation dis-
tance (proportional to r
6). The efﬁciency of the energy
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1224transfer can be determined from either steady-state or
time-resolved measurements. This property has been
extensively used in biological research to identify
protein interactions, monitor intracellular signaling
activities in real-time, and survey bioactive molecules
by high-throughput screening (HTS).
4,8,23 Compared
with traditional techniques to identify protein–protein
interactions, such as co-immunoprecipitation and
yeast two-hybrid assay, FRET offers real-time moni-
toring and spatial information on molecular interac-
tions in living cells.
29
BecauseofFRET’shighsensitivityandsuitabilityfor
both spectroscopy and imaging analysis, many eﬀorts
have been made to develop it into quantitative assays
and HTS assays.
2,4,8,23 However, due to the low FRET
efﬁciencies of ﬂuorescent proteins and complexity of
ﬂuorescence emissions of donor and acceptor, it has
been very challenging process in developing FRET into
quantitative assay until recently, an effort utilizing clas-
sical ECFP and Venus-YFP to measure Kd of SUMO1
and Ubc9 interaction.
17 In this study, CFP-tagged
SUMO1 and YFP-tagged Ubc9 recombinant proteins
were mixed and the ﬂuorescent spectrum was compared
with that from CFP and YFP–Ubc9 to derive the
FRET-sensitizedemissionfromYFP–Ubc9.TheFRET
emission intensity was then ﬁtted with YFP–Ubc9 con-
centration in a hyperbola curve to get the maximum
FRET emission intensity, and the bound YFP–Ubc9
concentration were calculated from the FRET emission
inalinearrelationship.FittingtheboundandfreeYFP–
Ubc9 concentrations with a hyperbola formula resulted
in a Kd value of 0.59 lM, which is very close to the Kd
determined by other methods.
26
Current FRET-based HTS assays have been mostly
limited to in vitro biochemical assay or small-molecule
ﬂuorophore in non-protein molecules due to their high
quantum yield or high FRET efﬁciency.
4,24 In these
assays, organic ﬂuorophores are used to modify pro-
teins of interest in vitro, and compound libraries are
added into recombinant protein mixtures. Although
in vitro assays based on puriﬁed recombinant proteins
are easier to handle, they do not accurately replicate
the intracellular environment, do not reﬂect the
localization and modiﬁcation of target proteins in liv-
ing cells, and cannot determine transport efﬁciencies of
the drug across cell membranes.
Here, we report the theoretical and experimental
developments for Kd determination of SUMO1 and
Ubc9 interaction, and HTS assay development in liv-
ing cells using an engineered FRET pair, CyPet and
YPet. This pair has been showed to have much higher
ﬂuorescence quantum yield and FRET efﬁciency.
19
The radiometric FRET signal of CyPet and YPet was
20-fold greater than that of CFP–YFP. This greatly
improved dynamic signal range makes CyPet and YPet
excellent candidate for both quantitative FRET-based
assays and HTS development for inhibitor screening of
protein–protein interactions. In contrast to traditional
ratiometric criteria of FRET signal, we have differen-
tiated and quantiﬁed absolute ﬂuorescence signals
contributed by each component, namely donor,
acceptor and FRET at the acceptor emission wave-
length, which was missed in the traditional ratiometric
measurement of FRET. We derived an improved
mathematic formula which directly connects the FRET
signal-to-Kd. The Kd of SUMO1 and Ubc9 has been
successfully determined using this technique, which ﬁts
very well with that determined by other methods, such
as surface plasmon resonance (SPR). The same FRET
pair, CyPet and YPet, has been used to develop
FIGURE 1. Multiple protein–protein interactions are involved in sumoylation conjugation pathway.
Development of FRET Assay 1225cell-based FRET HTS, which is pioneer in this ﬁeld.
Both Kd determination and cell-based HTS were per-
formed in 384-well plate format, which readily allows
repeated study and large-scale application, such as
genome-wild and industrial applications.
MATERIALS AND METHODS
DNA Constructs and Protein Expression
The open reading frames of the genes were ampliﬁed
by PCR and the PCR products were cloned into
pCRII-TOPO vector (Invitrogen). After sequencing
conﬁrmation, the cDNA encoding CyPet–SUMO1 and
YPet–Ubc9 were cloned into pcDNA3.1hygro and
pcDNA3.1V5His vectors (Invitrogen), respectively.
The cDNAs encoding SUMO1, Ubc9, CyPet–SUMO1
or YPet–Ubc9 were also cloned into pET28(b) vector
(Novagen).
BL21(DE3) Escherichia coli (E. coli) cells were
transformed with pET28 vectors encoding SUMO1,
Ubc9, CyPet–SUMO1 or YPet–Ubc9. The trans-
formed bacteria were inoculated in 2 9 YT medium
and the expression of polyhistidine-tagged recombinant
proteins was induced with 0.1 mM IPTG at 25  C
overnight. The recombinant proteins were puriﬁed by
Ni
2+–NTA agarose beads (QIAGEN) followed by gel
ﬁltration HPLC using Superdex75 10/300 GL column
on a HPLC puriﬁcation system (GE Healthcare,
A ¨ KTA
TM puriﬁer). YPet–Ubc9 and Ubc9 proteins
used for SPR analysis were digested by thrombin to
remove the polyhistidine tags prior to puriﬁcation by
HPLC.
FRET Assay and Kd Measurement
Recombinant CyPet–SUMO1 and YPet–Ubc9 pro-
teins were mixed and diluted with phosphate buﬀered
saline (PBS) to a total volume of 30 lL. The ﬁnal
concentration of CyPet–SUMO1 was ﬁxed to 1 lM
and the ﬁnal concentration of YPet–Ubc9 varied from
0t o4lM. The mixtures were transferred into a 384-
well plate (Falcon) and the ﬂuorescence emission
spectrum of each well was measured with a ﬂuorescence
multi-well plate reader (Molecular Devices, Flexsta-
tionII
384). Two excitation wavelengths were used:
414 nm to excite CyPet, and 475 nm to excite YPet.
Excited at 414 nm, CyPet has an emission peak at
475 nm (FLDD) (see Fig. 2). With FRET, another
emission peak at 530 nm (Emtotal) can be observed
which results from the energy transferred from CyPet
to YPet. When the mixture is excited at 475 nm, an
emission peak at 530 nm (FLAA) can be observed which
is from the direct excitation of YPet but not CyPet.
FIGURE 2. Design and detection of high sensitive FRET-based detection for protein interactions in sumoylation conjugation
cascade. (a) The diagram of FRET-based detection of SUMO1 and its E2 ligase, Ubc9, interaction. (b) Emission spectra of protein
mixtures with [CyPet–SUMO1] ﬁxed as 1 lM and [YPet–Ubc9] increased from 0 to 7.5 lM. Excitation wavelength is 414 nm.
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recombinant proteins was excited at 414 nm, the
emission intensity at 530 nm was consisted of three
components: the direct emission of CyPet, the sensi-
tized emission of YPet and the direct emission of YPet.
Because the sensitized emission from YPet–Ubc9
(EmFRET) is proportional to the amount of YPet–Ubc9
bound to CyPet–SUMO1 ([YPetUbc9]bound), we can
convert the concentration of YPet–Ubc9 in both free
([YPetUbc9]free) and bound ([YPetUbc9]bound) forms
to functions of EmFRET. Therefore, we can derive the
relationship between EmFRET and the total concen-
tration of YPet–Ubc9 ([YPetUbc9]total), and calculate
the Kd between CyPet–SUMO1 and YPet–Ubc9 based
on the algorithm we developed. Data were processed in
Prism 5 (GraphPad Software).
Surface Plasma Resonance Measurement
All analyses of interaction between CyPet–SUMO1
and YPet–Ubc9 or SUMO1 and Ubc9 were performed
on BIAcore X100 system equipped with NTA sensor
chips (BIAcore AB, Uppsala, Sweden) at a ﬂow rate of
30 lL/min. For immobilization of proteins, the chip
was treated with 500 lM NiCl2 for 1 min before 10 lg/
mL puriﬁed CyPet–SUMO1 or 4 lg/mL puriﬁed
SUMO1 protein was injected for 180 s and stabilized
for 60 s. Then 20–150 lg/mL thrombin-digested YPet-
Ubc9 or 5–50 lg/mL thrombin-digested Ubc9 protein
was injected for 90 or 120 s and disassociated for
10 min. In order to continuously monitor the non-
speciﬁc background binding of samples to the NTA
surface, YPet–Ubc9 and Ubc9 proteins were injected
into a control ﬂow cell without treatment of NiCl2 and
CyPet–SUMO1/SUMO1 proteins. All measurements
were performed at 25  C in a buffer containing 50 mM
sodium phosphate pH 7.4, 150 mM NaCl and 50 lM
EDTA. Data were analyzed with BIAcore X100 eval-
uation software ver.1.0 (BIAcore).
Mammalian Cell Culture and HTS assay
All cell culture supplies including media, serum, and
antibiotics were purchased from Invitrogen (Carlsbad,
CA). To generate cell lines which can stably express
CyPet–SUMO1 and YPet–Ubc9 proteins, HEK293
cells were transfected with pcDNA3.1hygro–CyPet–
SUMO1 using FuGene6 (Roche) in a 6-well plate,
diluted to several 10 cm dishes, and selected in DMEM
medium supplemented with 150 lg/mL hygromycin.
After 2 weeks, cell colonies were transferred and cul-
tured on 96-well plates. In order to determine the
expression of CyPet–SUMO1, the ﬂuorescence emis-
sion intensities of individual colonies at 475 nm
(excited at 414 nm) were scanned using FlexstationII
384
(Molecular Devices). The colony having the highest
emission intensity was picked up and expanded. This
CyPet–SUMO1-expressing HEK293 stable cell line
was then transfected with pcDNA3.1V5His–YPet–
Ubc9 and selected with 750 lg/mL geneticin for
2 weeks. The ﬂuorescence intensities of cell colonies at
475 and 530 nm (excited at 414 nm) were measured
using FlexstationII
384 (Molecular Devices), and the
colony having the highest Em530/Em475 ratio was
picked up and used for subsequent screening assays.
HEK293 cells stably expressing CyPet–SUMO1 and
YPet–Ubc9 were diluted to 500 cells per microliter
with PBS. Sixty microliter resuspended cells were then
aliquoted into each well of 384-well plates (Falcon)
using a liquid handler (Molecular Devices, AquaMax
DW4). To screen the compound library for inhibitors
of SUMO1–Ubc9 interactions, 1 lL 500 lM chemical
compound was added to each well using the liquid
handling module of FlexstationII
384 (Molecular
Devices). After incubation at 37  C for 2 h, they were
excited at 414 nm and the ﬂuorescence emission
intensities of each well at 475 nm [Em475(Ex414)] and
530 nm [Em530(Ex414)] were measured using Flexsta-
tionII
384. The emission ratio of Em530(Ex414)t o
Em475(Ex414) was then calculated for all the wells.
RESULTS
Fluorescence Spectrum Analysis of FRET Signal
Dissociation constant, Kd, is an important param-
eter for characterizing protein–protein interactions.
Based on the fact that FRET signal is proportional to
the amount of bound FRET pair, we developed a
FRET-based technology for Kd determination. We
believe that FRET-based technology could provide
unique advantages compared to traditional techniques
for Kd determination, such as BIAcore SPR or radio-
labeled-ligand binding assay. FRET technology allows
real-time monitoring of protein interactions even in a
multiple protein complex. The instrumentations for
FRET measurement are widely available.
15,22 No
radioisotope labeling is required, providing environ-
mental-friendly approach. Furthermore, protein con-
centrations in the system can be accurately determined
by ﬂuorescent emission intensity and quantum yield.
17
We chose SUMOylation pathway as our model
system for this technology development because this
pathway involves multiple protein–protein interac-
tions,
13 and is also a good potential pathway for
chemical inhibitor discovery with our technology (see
below). There are two levels of interactions between
SUMO1 and it E2 ligase, Ubc9: non-covalent and
covalent interactions (Fig. 2a). The non-covalent
Development of FRET Assay 1227physical interaction of these two proteins brings two
proteins together without any SUMO activation.
14 On
the other hand, covalent interaction results from an
isopeptide bond formation between the C-terminal Gly
of SUMO and the Cysteine 93 of Ubc9 after the acti-
vation of SUMO peptide by its E1 activating enzyme.
To determine the Kd of non-covalent interaction of
SUMO1 and Ubc9 by FRET approach, we chose a
FRET pair, CyPet and YPet, to label SUMO1 and
Ubc9 because of their improved FRET efﬁciency.
19
The excitation and emission wavelength of CyPet and
YPet are around 414 and 475 nm, 515 and 530 nm,
respectively. Speciﬁcally, the open reading frames of
CyPet and YPet were ﬁrst ligated into pCRII-TOPO
and fused to SUMO1 and Ubc9, respectively. The
fusion genes of CyPet–SUMO1 and YPet–Ubc9 were
then ligated into pET28 bacterial expression vector.
The fusion proteins with poly-histidine and ﬂuorescent
tags were then expressed in E. coli and puriﬁed by
Ni–NTA afﬁnity column followed by HPLC gel ﬁl-
tration puriﬁcation. To implement FRET-based tech-
nology for Kd determination, two key issues need to be
solved. First, we need to differentiate and quantify
ﬂuorescence signal of FRET from other direct ﬂuo-
rescence signals of donor and acceptor at the excitation
wavelength. Second, we need to convert ﬂuorescence
signals to corresponding concentrations of bound
partners, donor and acceptor proteins. We started with
the general law of mass action for protein–protein
interaction.
SUMO1 þ UBC9 $ SUMO1 UBC9
The Kd for this pair can be calculated as following
Kd ¼
½CyPetSUMO1 free½YPetUbc9 free
½CyPetSUMO1   YPetUbc9 
¼
½CyPetSUMO1 free½YPetUbc9 free
½YPetUbc9 bound
ð1Þ
We then diﬀerentiate the ﬂuorescent signals at
530 nm into three fractions: FRET emission
(EmFRET), YPet direct emission, and CyPet direct
emission when excited at 414 nm (Eq. 2; Fig. 3a),
EmFRET ¼ð EmtotalÞ CyPetðcontÞ YPetðcontÞð 2Þ
where CyPet(cont) is the ﬂuorescence signal contribu-
tion of donor, YPet(cont) is the ﬂuorescence signal
contribution of acceptor.
We then speculated and found out that the direct
emission of donor, CyPet, at 530 nm is proportional to
its emission at 475 nm when excited at 414 nm with a
ratio factor of x, while the direct emission of acceptor,
YPet, at 530 nm is proportional to its emission at
530 nm when excited at 475 nm with a ratio factor of
y (Eq. 3;F i g .3b).
EmFRET ¼ð EmtotalÞ ð x   FLDDÞ ð y   FLAAÞð 3Þ
where FLDD is ﬂuorescence signal of donor when
excited at donor wavelength (414 nm), and FLAA is
ﬂuorescence signal of acceptor when excited at
acceptor wavelength (475 nm). From a series mea-
surement of different concentrations of CyPet alone
or YPet alone, we determined x = 0.378 and
y = 0.026.
FIGURE 3. Spectrum analysis of FRET signals. (a) Dissection of emission spectra from mixture of CyPet–SUMO1 and YPet–Ubc9.
(b) Emission spectrum of YPet equations used to determine sensitized FRET emission, to convert sensitized emission intensity to
bound concentration, to calculate the concentration of free YPet–Ubc9 and to ﬁt bound concentration against free concentration to
get the Kd value.
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and Ubc9 Interaction by FRET
In order to determine the Kd between SUMO1 and
Ubc9, we need to convert the protein concentrations to
functions of FRET signal intensity and derive its
relationship with Kd. Because the total concentration
of CyPet–SUMO1 in our assay is ﬁxed, the formula of
Kd (Eq. 1) can be expressed as:
Equation 4 can be converted to:
½YPetUbc9 bound ¼
½YPetUbc9 boundmax½YPetUbc9 free
Kd þ½ YPetUbc9 free
ð5Þ
Because the FRET signal intensity (EmFRET)i s
proportional to the concentration of bound YPetUbc9
in the mixture with all other parameters ﬁxed,
[YPetUbc9]bound in each condition is then determined
by the sensitized emission intensity in a linear rela-
tionship:
½YPetUbc9 bound ¼½ YPetUbc9 boundmax  
EmFRET
EmFRETmax
ð6Þ
Combining Eqs. (5) and (6) yields:
EmFRET ¼ EmFRETmax  
½YPetUbc9 free
Kd þ½ YPetUbc9 free
ð7Þ
If we set the total concentration of CyPet–SUMO1
to a constant a and the concentration of total and free
YPet–Ubc9 to variables X and Y, respectively, we can
convert the concentration of bound YPet–Ubc9 and
free CyPet–SUMO1 to:
½YPetUbc9 bound ¼ X   Y ð8Þ
½CyPetSUMO1 free ¼a ½YPetUbc9 bound ¼a XþY
ð9Þ
Based on the deﬁnition of Kd and Eqs. (8) and (9),
we can derive
Kd ¼
½CyPetSUMO1 free½YPetUbc9 free
½YPetUbc9 bound
¼
ða   XþYÞ Y
X   Y
We then solved the above equation as following,
Y2   XY þ aY ¼ KdX   KdY
Y2  ð X   a   KdÞY   KdX ¼ 0
Y ¼
1
2
ðX   a   Kd þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðX   a   KdÞ
2 þ 4KdXÞ
q
ð10Þ
Combining Eqs. (7) and (10) yields:
EmFRET¼
EmFRETmax 1 
2Kd
X aþKdþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðX a KdÞ
2þ4KdX
q
0
B @
1
C A
ð11Þ
Therefore, by ﬁtting the dataset of EmFRET and
total YPet–Ubc9 concentration (X) with Eq. (11)w e
will be able to derive the value of maximum EmFRET
(EmFRETmax) and Kd.
Before we measured the FRET signals between
CyPet–SUMO1 and YPet–Ubc9, we ﬁrst characterized
potential interaction interference of tags used in our
assay, poly-His, CyPet and YPet because it was
reported that CyPet and YPet may have a weak
dimerization activity by themselves. We would like to
know any potential interaction aﬃnity from these tags.
A dose-dependent FRET signal increase was observed
for CyPet–SUMO1 and YPet–Ubc9, while as control
pairs all with poly-His tag, CyPet and YPet, CyPet and
YPet–Ubc9, or CyPet–SUMO1 and YPet did not show
any signiﬁcant FRET signals within the experimental
concentration (Fig. 4a). These results suggest that, in
our experimental condition, these tags would not form
a dimmer by themselves and therefore generate inter-
ference for Kd measurement of SUMO1 and Ubc9.
In our Kd determination experiment, we ﬁxed the
CyPet–SUMO1 concentration to 1 lM and increased
the concentration of YPet–Ubc9 from 0 to 4 lMi na
total volume of 30 lL. The ﬂuorescence emission
spectra of the mixture were then determined by
FlexstationII
384 under excitation wavelength of 414 nm
(Fig. 2b) or 475 nm (data not shown). After the FRET
emission intensity under each condition was calculated,
thedatasetofEmFRETand[YPetUbc9]totalwereﬁttedin
Eq. (11)byleast-square ﬁtting withconstant aﬁxedto 1
(Fig. 4b).WegotanEmFRETmax of (2.38 ± 0.05) 9 10
5
Kd ¼
f½CyPetSUMO1 total  ½ YPetUbc9 boundg½YPetUbc9 free
½YPetUbc9 bound
¼
f½YPetUbc9 boundmax  ½ YPetUbc9 boundg½YPetUbc9 free
½YPetUbc9 bound
ð4Þ
Development of FRET Assay 1229RFUandKdof0.33 ± 0.04 lM,whichiscomparableto
the previously published results from Martin et al.
17
(0.59 ± 0.09 lM) and Tatham et al.
26 (0.25 ±
0.07 lM).
Kd Determination of the Non-covalent SUMO1
and Ubc9 Interaction by SPR
To validate our results of Kd measurement from the
FRET assay, we then measured the interaction afﬁnity
of CyPet–SUMO1 and YPet–Ubc9 by SPR. His-tagged
CyPet–SUMO1 was expressed in bacterial cells and
puriﬁed using Ni–NTA agarose beads. After dialysis,
His-tagged CyPet–SUMO1 was immobilized onto a
SPR NTA sensor chip. YPet–Ubc9 was obtained by
cleaving the His-tagged YPet–Ubc9 on Ni beads
directly by thrombin digestion. The cleaved YPet–Ubc9
was then further puriﬁed by HPLC. Non-speciﬁc
binding of YPet–Ubc9 to the NTA chip was subtracted
as described in ‘‘Materials and Methods’’ section.
The binding kinetics analysis showed the binding
response of the bound CyPet–SUMO1 to injections of a
series of different concentrations of YPet–Ubc9
(Fig. 5a). CyPet–SUMO1 bound with moderate kinet-
ics to YPet–Ubc9, with a calculated Kd of 0.35 lM.
This Kd is consistent with the Kd of 0.33 ± 0.04 lM
determined by FRET assay described above.
To further analyze the possible interference of
ﬂuorescence tag to the interaction, we performed a
control experiment in SPR. The interaction of SUMO1
and Ubc9 by themselves was analyzed. Similar to
above experiment, His-tagged SUMO1 was immobi-
lized onto NTA sensor chip. Cleaved Ubc9 was puri-
ﬁed by HPLC. Bound SUMO1 shows binding response
to a series of injected diﬀerent Ubc9 concentrations in
a similar kinetics as ﬂuorescent protein-tagged fusion
proteins (Fig. 5b). The Kd of SUMO1 and Ubc9
interaction was calculated as 0.1 lM, which is com-
parable with that of ﬂuorescent protein-tagged
SUMO1 and Ubc9.
FIGURE 4. Determination of interaction afﬁnity Kd between CyPet–SUMO1 and YPet–Ubc9 using FRET technology. (a) Interaction
speciﬁcity and quantitation among pairs. (b) Plot of FRET-sensitized YPet–Ubc9 emission vs. the total YPet–Ubc9 concentration.
FIGURE 5. Determination of interaction afﬁnity Kd by surface plasma resonance measurement. (a) Determination of Kd between
CyPet–SUMO1 and YPet–Ubc9 using BIAcore, resulting in Kd 5 0.35 lM. (b) Determination of Kd between SUMO1 and Ubc9 using
BIAcore, resulting in Kd 5 0.10 lM.
SONG et al. 1230Development of Cell-Based HTS Assay
Although FRET assay has been widely used in basic
research, it has not been robustly developed into HTS
format, especially in cell-based HTS because of the
challenging requirements of high signal-to-noise ratio
and low variation.
4,24 To explore whether this FRET
pair can be developed into HTS platform, we went
further to test whether this FRET assay is suitable for
HTS format or not. In general, a large number of
compounds (>100,000 compounds) and various
robots normally involved in HTS require reproducible,
low variation and cost-effective biological assays. For
the FRET-based screening platform, the ideal assay
would use cell lines stably expressing ﬂuorescence
donor and acceptor pairs in which FRET signals are
strong enough to be detected by HTS instruments,
such as plate readers.
Establish Stable Cell Lines Expressing Cypet–SUMO1
and Ypet–Ubc9 for Cell-Based FRET Screening
To achieve high reproducibility, low variation and
low cost for HTS, a stable cell line expressing both
CyPet–SUMO1 and YPet–Ubc9 was established
(‘‘Materials and Methods’’ section). Brieﬂy, we gener-
ated the stable cell line in a sequential manner. We ﬁrst
introduced CyPet–SUMO1 into HEK293 cells and
selected cell lines with high level of CyPet expression.
Then we introduced the second partner, YPet–Ubc9.
After the second selection, individual stable colonies
were picked up and their FRET signals were examined
(Fig. 6a). We also generated control cell lines
expressing only CyPet–SUMO1 alone and with other
YPet pair, such as YPet–Aos1 for HTS and follow-up
assays. When the cells were excited at 414 nm, we
routinely got emission ratio (Em530/Em475) of stable
cell lines at around 0.8–1.2 (Fig. 6b), while as that of
the control cell line (CyPet–SUMO1) was 0.4–0.6.
Typical spectrums of stable cell line and control cells
were shown in Fig. 6b when exited at 414 nm and in
Fig. 6c when exited at 475 nm. To further validate the
results, we also carried out the FRET assay with
ﬂuorescence microscopy imaging measurements. The
cells stably expressing CyPet–SUMO1/YPet–Ubc9
showed ﬂuorescence emission in the yellow channel
when excited at 442 nm, while the control cells stably
expressing CyPet–SUMO1 showed little ﬂuorescence
emission in the yellow channel when excited at the
same wavelength (Fig. 6d).
To estimate the dynamic range of FRET signal
changes of the stable cell line in oder to estimate the
screening criteria, we performed SUMO1/Ubc9 dis-
ruption assays using detergent and/or urea, which
could disrupt protein–protein interactions. To get a
FIGURE 6. Characterizations of stable cell line for FRET assay. (a) FRET characterization of individual stable cell lines.
(b) Fluorescence spectrum of control cells, single transfected stable cell line, and double transfected stable cell line when excited
at 414 nm. (c) Fluorescence spectrum of control cells, single transfected stable cell line, and double transfected stable cell line
when excited at 465 nm. (d) Fluorescence image analysis of stable cell lines.
Development of FRET Assay 1231full range of FRET signals with no interactions of the
FRET pair, we examined the FRET spectrum of stable
cells in PBS or lysed cells using lysis buﬀer containing
200 mM NaCl, 10 mM Tris with 1.0% Triton X100, or
lysis buﬀer plus 1 M urea. The FRET signal was
decreased from 1.2 to 0.6 by the lysis buﬀers or lysis
buﬀer plus urea (Fig. 7a). Even with 1 M urea, the
FRET signal did not decrease any further, indicating
that all the interactions of CyPet–SUMO1/YPet–Ubc9
had been fully disrupted. The dynamic range of FRET
signal from 1.2 to 0.6 reﬂects from the full interaction
to no interaction of CyPet–SUMO1 and YPet–Ubc9,
which will be used as criteria for the screening hit
pickup (Fig. 7b and see below for Pilot screening).
Assay Development in the 384-Well Plate Format
and Pilot Screening
A highly predictable and reproducible assay is
required for HTS and miniaturization is a critical step
in the HTS development.
24 We thus attempted to
develop this FRET-based Ubc9 inhibitor screening into
a consistent and high signal-to-noise assay. In principle,
a hit should generate a signal in an assay with 95–99%
conﬁdence depending on the screens. That means that
a hit should be picked by its signal at least beyond
three SDs. To achieve high-quality HTS, the ratio-
metric FRET signal (R = Em530nm/Em475nm) was used
as screening signal and the coefﬁcient of variation (CV)
of signals in 384-well plate format was used as a var-
iation assessment. We tested different numbers of cells/
well and measured the above parameters for different
times on different days. Consistent results were
obtained. The ratiometric FRET signal (R = Em530nm/
Em475nm) of the stable cell line expressing CyPet–
SUMO1/YPet–Ubc9 was 1.14 ± 0.04. The signal of
the control stable cell line expressing CyPet–SUMO1
was 0.54 ± 0.03. The CVs of all the samples were less
than 10%, which met the criteria of HTS requirement,
15%. These data indicate that signal-to-noise is quite
separated with tight variations. These results suggest
that screening inhibitor(s) of SUMO1–Ubc9 interac-
tion in 384-well plates is feasible for HTS.
To validate our FRET-based HTS platform, we
conducted a small-scale pilot screening with a fraction
of compound collections available to us. We screened
2000 compounds and found the mean of Em530/Em475
to be 0.95 and standard deviation (SD) to be 0.15.
After we ﬁltered out ﬁve right side outliers (Em530/
Em475>3.0), the FRET signals of most compounds
were centered at mean. The cut-off of primary hits was
set up below 3 9 SD, which the ratio of Em530/Em475
is 0.5. A total of 136 hits were picked up and the hit
rate was 1.13%. After ﬁltered out those compounds
(97 compounds) with self-ﬂuorescence, 39 compounds
were kept for further validation and characterization.
These data are compatible to a typical HTS hit rate,
indicating that this assay platform is feasible for HTS.
DISCUSSION
The high eﬃcient FRET pair, CyPet and YPet, has
provided suitable tools for both Kd measurements and
HTS assay development in living cells. We have dem-
onstrated a robust approach for Kd measurement in
solution using FRET assay in steady state. The Kd from
FRET assay has been validated by other traditional
methods, such as SPR. Another group also demon-
strated the application of FRET assay using classical
CFP and YFP for Kd measurement. We have derived a
signiﬁcantly different and improved theoretical and
experimental procedure to derive Kd from ﬂuorescent
signal by characterizing the quantitative contributions
FIGURE 7. Reversible interaction of SUMO1 and Ubc9 in living cells. (a) FRET assays of stable HEK293 cell line containing CyPet–
SUMO1 and YPet–Ubc9 after different treatments with or without protein interaction disrupting reagents, such as Triton-100 or
Urea. (b) Plot of FRET ratio (Em530/Em475) of cells treated with or without disrupting buffers as in (a). (c) Positive hit selection of
seven hundred screened compounds.
SONG et al. 1232of donor and acceptor alone and FRET signal. This
novel mathematic algorithm of FRET analysis and
simpliﬁed experimental method enable us to measure
Kd using one formula and derive more accurate Kd
because of the elimination of a step for the estimation
of maximum bound protein in the middle step. This
novel method not only saves the experimental steps but
also provide more rigorous mathematic process than
the multi-step approach. The data derived from our
approach ﬁts into the same category of data determined
by other approach and are very tight to each others.
17,26
This has demonstrated that interaction afﬁnity mea-
surement by FRET assay is not only feasible but also
accurate. This novel approach would provide a very
convenient way for Kd measurement.
Although FRET assay has been widely used in
protein–protein interaction assay using in vitro and
spectroscopic method, it has not been developed into a
robust HTS technology.
4,19,24 Our FRET assay targets
protein–protein interactions in vivo. The cell-based
HTS will serve as homogenous cell-based assay and
will not necessarily reﬂect a direct physical interaction
of two proteins, but its cellular interaction activity
which could be mediated by other partner(s). The
compounds need to permeate the mammalian cell
membrane in order to show activity in this cell-based
assay. Therefore, there will be some discrepancy of
compound behavior between in vitro assay and in cell-
based assay, which is a very challenging task in phar-
maceutical industry. In addition, the screening com-
pounds need to be stable in cell culture medium and in
cytoplasm, which provide another level testing for
compounds to be effective inside cells.
The strategy using ﬂuorescent proteins as ﬂuorescent
marker for bound and free partner measurements can
be a general method for determining interaction aﬃn-
ities of protein–protein interactions and HTS technol-
ogy.
5,21,29 The approach can be used to measure afﬁnity
involving multiple proteins. There are several advan-
tages of FRET-based Kd measurement and HTS in
living cells over other methods. First, this approach is
environmentally friendly, which only requires DNA
constructions without radioisotope labeling. Second,
the ﬂuorescent-tagged proteins are in aqueous phase,
which is mostly close to their natural environment in
cells. Third, the ﬂuorescence intensity can be deter-
mined by general ﬂuorescence spectroscopy or ﬂuo-
rescence plate reader, which is widely available. Finally,
cell-based FRET screening of protein–protein interac-
tion inhibitors is a new screening approach, which not
only provides robustness of screening but also evaluate
properties of chemical compounds for stability and
membrane permeability at the same time. Therefore,
the high sensitive FRET-based assays could be a
powerful approach in developing genome-wide protein
interaction afﬁnity determination and inhibitor
screenings of protein–protein interaction.
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